Skip to main content

Articles

Page 5 of 94

  1. Integrase strand transfer inhibitors (INSTIs) are recommended for first-line HIV therapy based on their relatively high genetic barrier to resistance. Although raltegravir (RAL) and elvitegravir (EVG) resistan...

    Authors: Maureen Oliveira, Ruxandra-Ilinca Ibanescu, Kaitlin Anstett, Thibault Mésplède, Jean-Pierre Routy, Marjorie A. Robbins and Bluma G. Brenner
    Citation: Retrovirology 2018 15:56
  2. The induction of HIV-1-specific antibodies that can neutralize a broad number of isolates is a major goal of HIV-1 vaccination strategies. However, to date no candidate HIV-1 vaccine has successfully elicited ...

    Authors: Eirini Moysi, Constantinos Petrovas and Richard A. Koup
    Citation: Retrovirology 2018 15:54
  3. HIV-1 Env gp160 is cleaved to form gp120 and gp41 and the functional HIV-1 Env is a trimer of non-covalently associated heterodimeric subunits, gp120 and gp41. The cleaved, native, trimeric form of Envs expose...

    Authors: Sweety Samal, Supratik Das, Saikat Boliar, Huma Qureshi, Tripti Shrivastava, Naresh Kumar, Sandeep Goswami, Manish Bansal and Bimal K. Chakrabarti
    Citation: Retrovirology 2018 15:50
  4. Semen is a critical vector for human immunodeficiency virus (HIV) sexual transmission and harbors seminal amyloid fibrils that can markedly enhance HIV infection. Semen-derived enhancer of viral infection (SEV...

    Authors: Ruxia Ren, Shuwen Yin, Baolong Lai, Lingzhen Ma, Jiayong Wen, Xuanxuan Zhang, Fangyuan Lai, Shuwen Liu and Lin Li
    Citation: Retrovirology 2018 15:49
  5. Nuclear localization of Gag is a property shared by many retroviruses and retrotransposons. The importance of this stage for retroviral replication is still unknown, but studies on the Rous Sarcoma virus indic...

    Authors: Joris Paris, Joëlle Tobaly-Tapiero, Marie-Lou Giron, Julien Burlaud-Gaillard, Florence Buseyne, Philippe Roingeard, Pascale Lesage, Alessia Zamborlini and Ali Saïb
    Citation: Retrovirology 2018 15:48
  6. The ability of HIV-1 to integrate into the genomes of quiescent host immune cells, establishing a long-lived latent viral reservoir (LVR), is the primary obstacle to curing these infections. Quantitative viral...

    Authors: Art F. Y. Poon, Jessica L. Prodger, Briana A. Lynch, Jun Lai, Steven J. Reynolds, Jingo Kasule, Adam A. Capoferri, Susanna L. Lamers, Christopher W. Rodriguez, Daniel Bruno, Stephen F. Porcella, Craig Martens, Thomas C. Quinn and Andrew D. Redd
    Citation: Retrovirology 2018 15:47
  7. Development of AIDS vaccines for effective prevention of circulating HIV-1 is required, but no trial has demonstrated definitive effects on the prevention. Several recent T-cell vaccine trials showed no protec...

    Authors: Hayato Murakoshi, Chengcheng Zou, Nozomi Kuse, Tomohiro Akahoshi, Takayuki Chikata, Hiroyuki Gatanaga, Shinichi Oka, Tomáš Hanke and Masafumi Takiguchi
    Citation: Retrovirology 2018 15:46
  8. Co-infection with avian leukosis virus subgroup J and reticuloendotheliosis virus induces synergistic pathogenic effects and increases mortality. However, the role of exosomal miRNAs in the molecular mechanism...

    Authors: Defang Zhou, Jingwen Xue, Shuhai He, Xusheng Du, Jing Zhou, Chengui Li, Libo Huang, Venugopal Nair, Yongxiu Yao and Ziqiang Cheng
    Citation: Retrovirology 2018 15:45
  9. Viral reprogramming of host cells enhances replication and is initiated by viral interaction with the cell surface. Upon human immunodeficiency virus (HIV) binding to CD4+ T cells, a signal transduction cascad...

    Authors: Danica D. Wiredja, Caroline O. Tabler, Daniela M. Schlatzer, Ming Li, Mark R. Chance and John C. Tilton
    Citation: Retrovirology 2018 15:44
  10. The ability of human immunodeficiency virus type 1 (HIV-1) to form a stable viral reservoir is the major obstacle to an HIV-1 cure and post-transcriptional events contribute to the maintenance of viral latency...

    Authors: Shringar Rao, Raquel Amorim, Meijuan Niu, Abdelkrim Temzi and Andrew J. Mouland
    Citation: Retrovirology 2018 15:42
  11. HIV-1 transcription activator protein Tat is phosphorylated in vitro by CDK2 and DNA-PK on Ser-16 residue and by PKR on Tat Ser-46 residue. Here we analyzed Tat phosphorylation in cultured cells and its functi...

    Authors: Andrey Ivanov, Xionghao Lin, Tatiana Ammosova, Andrey V. Ilatovskiy, Namita Kumari, Hatajai Lassiter, Nowah Afangbedji, Xiaomei Niu, Michael G. Petukhov and Sergei Nekhai
    Citation: Retrovirology 2018 15:39
  12. Hosts are able to restrict viral replication to contain virus spread before adaptive immunity is fully initiated. Many viruses have acquired genes directly counteracting intrinsic restriction mechanisms. This ...

    Authors: Carmen Ledesma-Feliciano, Sarah Hagen, Ryan Troyer, Xin Zheng, Esther Musselman, Dragana Slavkovic Lukic, Ann-Mareen Franke, Daniel Maeda, Jörg Zielonka, Carsten Münk, Guochao Wei, Sue VandeWoude and Martin Löchelt
    Citation: Retrovirology 2018 15:38
  13. Different classes of latency reversing agents (LRAs) are being evaluated to measure their effects in reactivating HIV replication from latently infected cells. A limited number of studies have demonstrated add...

    Authors: Georges Khoury, Talia M. Mota, Shuang Li, Carolin Tumpach, Michelle Y. Lee, Jonathan Jacobson, Leigh Harty, Jenny L. Anderson, Sharon R. Lewin and Damian F. J. Purcell
    Citation: Retrovirology 2018 15:36
  14. Adult T-cell leukemia/lymphoma (ATL) is an aggressive malignancy secondary to chronic human T-cell lymphotropic virus 1 infection, triggered by the virally encoded oncoprotein Tax. The transforming activity an...

    Authors: Rita Hleihel, Behzad Khoshnood, Ingrid Dacklin, Hayssam Omran, Carine Mouawad, Zeina Dassouki, Marwan El-Sabban, Margret Shirinian, Caroline Grabbe and Ali Bazarbachi
    Citation: Retrovirology 2018 15:33
  15. The apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3 (APOBEC3; A3) gene family appears only in mammalian genomes. Some A3 proteins can be incorporated into progeny virions and inhibit lentivir...

    Authors: Yoriyuki Konno, Shumpei Nagaoka, Izumi Kimura, Keisuke Yamamoto, Yumiko Kagawa, Ryuichi Kumata, Hirofumi Aso, Mahoko Takahashi Ueda, So Nakagawa, Tomoko Kobayashi, Yoshio Koyanagi and Kei Sato
    Citation: Retrovirology 2018 15:31
  16. Among the different markers of HIV persistence in infected cells, total HIV DNA is to date the most widely used. It allows an overall quantification of all viral forms of HIV DNA in infected cells, each playin...

    Authors: Christine Rouzioux and Véronique Avettand-Fenoël
    Citation: Retrovirology 2018 15:30
  17. The native pre-fusion structure of gp120/gp41 complex of human immunodeficiency virus type 1 was recently revealed. In the model, the helices of gp41 (α6, α7, α8, and α9) form a four-helix collar underneath trime...

    Authors: Dehua Liu, Hongyun Wang, Mizuki Yamamoto, Jiping Song, Rui Zhang, Qingling Du, Yasushi Kawaguchi, Jun-ichiro Inoue and Zene Matsuda
    Citation: Retrovirology 2018 15:27
  18. The InterFeron Induced TransMembrane (IFITM) proteins are interferon stimulated genes that restrict many viruses, including HIV-1. SAMHD1 is another restriction factor blocking replication of HIV-1 and other v...

    Authors: Ferdinand Roesch, Molly OhAinle and Michael Emerman
    Citation: Retrovirology 2018 15:26
  19. NSC260594, a quinolinium derivative from the NCI diversity set II compound library, was previously identified in a target-based assay as an inhibitor of the interaction between the HIV-1 (ψ) stem-loop 3 (SL3) ...

    Authors: Carin K. Ingemarsdotter, Jingwei Zeng, Ziqi Long, Andrew M.L. Lever and Julia C. Kenyon
    Citation: Retrovirology 2018 15:25
  20. The initial envelope (Env)-specific antibody response in acutely HIV-1-infected individuals and simian immunodeficiency virus (SIV)-infected rhesus monkeys (RMs) is dominated by non-neutralizing antibodies tar...

    Authors: Quang N. Nguyen, David R. Martinez, Jonathon E. Himes, R. Whitney Edwards, Qifeng Han, Amit Kumar, Riley Mangan, Nathan I. Nicely, Guanhua Xie, Nathan Vandergrift, Xiaoying Shen, Justin Pollara and Sallie R. Permar
    Citation: Retrovirology 2018 15:24
  21. Antiretroviral therapy cannot cure HIV-1 infection due to the persistence of a small number of latently infected cells harboring replication-competent proviruses. Measuring persistent HIV-1 is challenging, as ...

    Authors: Zheng Wang, Francesco R. Simonetti, Robert F. Siliciano and Gregory M. Laird
    Citation: Retrovirology 2018 15:21
  22. Retroviruses can cause severe diseases such as cancer and acquired immunodeficiency syndrome. A unique feature in the life cycle of retroviruses is that their RNA genome is reverse transcribed into double-stra...

    Authors: Xu Zhang, Xiancai Ma, Shuliang Jing, Hui Zhang and Yijun Zhang
    Citation: Retrovirology 2018 15:20
  23. Simian immunodeficiency viruses (SIVs) of chimpanzees and gorillas from Central Africa crossed the species barrier at least four times giving rise to human immunodeficiency virus type 1 (HIV-1) groups M, N, O ...

    Authors: Mirela D’arc, Carolina Furtado, Juliana D. Siqueira, Héctor N. Seuánez, Ahidjo Ayouba, Martine Peeters and Marcelo A. Soares
    Citation: Retrovirology 2018 15:19
  24. Damage to the central nervous system during HIV infection can lead to variable neurobehavioral dysfunction termed HIV-associated neurocognitive disorders (HAND). There is no clear consensus regarding the neuro...

    Authors: Stephanie J. Bissel, Kate Gurnsey, Hank P. Jedema, Nicholas F. Smith, Guoji Wang, Charles W. Bradberry and Clayton A. Wiley
    Citation: Retrovirology 2018 15:17
  25. Although antiretroviral therapy is able to suppress HIV replication in infected patients, the virus persists and rebounds when treatment is stopped. In order to find a cure that can eradicate the latent reserv...

    Authors: Sofie Rutsaert, Kobus Bosman, Wim Trypsteen, Monique Nijhuis and Linos Vandekerckhove
    Citation: Retrovirology 2018 15:16
  26. Characterizing HIV genetic diversity and evolution during antiretroviral therapy (ART) provides insights into the mechanisms that maintain the viral reservoir during ART. This review describes common methods u...

    Authors: Gert van Zyl, Michael J. Bale and Mary F. Kearney
    Citation: Retrovirology 2018 15:14
  27. Cell-associated (CA) HIV RNA has received much attention in recent years as a surrogate measure of the efficiency of HIV latency reversion and because it may provide an estimate of the viral reservoir size. Th...

    Authors: Alexander O. Pasternak and Ben Berkhout
    Citation: Retrovirology 2018 15:13
  28. The multiple roles of both viral and cellular RNAs have become increasingly apparent in recent years, and techniques to model them have become significantly more powerful, enabling faster and more accurate vis...

    Authors: Dhivya Jayaraman and Julia Claire Kenyon
    Citation: Retrovirology 2018 15:11
  29. The retrovirus murine leukemia virus (MuLV) has an 8.3 kb RNA genome with a simple 5′-gag-pol-env-3′ architecture. Translation of the pol gene is dependent upon readthrough of the gag UAG stop codon; whereas the

    Authors: Nerea Irigoyen, Adam M. Dinan, Ian Brierley and Andrew E. Firth
    Citation: Retrovirology 2018 15:10
  30. The factors determining differential HIV disease outcome among individuals expressing protective HLA alleles such as HLA-B*27:05 and HLA-B*57:01 remain unknown. We here analyse two HIV-infected subjects expre...

    Authors: Jacqui Brener, Astrid Gall, Jacob Hurst, Rebecca Batorsky, Nora Lavandier, Fabian Chen, Anne Edwards, Chrissy Bolton, Reena Dsouza, Todd Allen, Oliver G. Pybus, Paul Kellam, Philippa C. Matthews and Philip J. R. Goulder
    Citation: Retrovirology 2018 15:7
  31. The HIV-1 accessory proteins Nef and Vpu alter cell surface levels of multiple host proteins to modify the immune response and increase viral persistence. Nef and Vpu can downregulate cell surface levels of th...

    Authors: Emily N. Pawlak, Brennan S. Dirk, Rajesh Abraham Jacob, Aaron L. Johnson and Jimmy D. Dikeakos
    Citation: Retrovirology 2018 15:6

Annual Journal Metrics

  • 2022 Citation Impact
    3.3 - 2-year Impact Factor
    3.8 - 5-year Impact Factor
    1.004 - SNIP (Source Normalized Impact per Paper)
    0.892 - SJR (SCImago Journal Rank)

    2023 Speed
    8 days submission to first editorial decision for all manuscripts (Median)
    83 days submission to accept (Median)

    2023 Usage 
    932,795 downloads
    667 Altmetric mentions